On This Day in Health: June 27, 2024
On June 27, 2024, the U.S. Food and Drug Administration authorized marketing of the first hepatitis C RNA test intended for use at the point of care. Cepheid's Xpert HCV test, used with the GeneXpert Xpress System, could detect the virus from a fingerstick blood sample and return a result in about an hour. The decision brought molecular diagnosis closer to the places where people already received services, including appropriately certified clinics and other treatment settings. It addressed a practical weakness in hepatitis C care: a person could begin the testing process yet never reach the confirmed diagnosis needed to move toward treatment.
Hepatitis C can persist without obvious symptoms while damaging the liver. Effective antiviral treatment was already available, but getting from an initial screening result to care could involve several appointments. An antibody test can show that someone has been exposed to the virus; it does not by itself establish that an infection is active. Detecting viral RNA helps answer that different question. When a blood sample must travel to a separate laboratory, the result may arrive after the person has left. Each additional visit can make follow-up harder, especially for people facing transportation problems, unstable access to care, or other barriers to returning.
The newly authorized test created the possibility of confirming infection and discussing treatment during the same visit. Its CLIA waiver allowed use in settings operating under the appropriate laboratory certification, with trained personnel following the test's instructions. It was not an authorization for people to diagnose themselves at home. Nor did the cartridge itself treat hepatitis C: clinicians still needed to evaluate a patient and arrange suitable medication and follow-up. The authorization also carried defined limits, including that the test was not intended to monitor treatment or screen donated blood. Like other diagnostic tools, its results had to be considered within an appropriate clinical evaluation.
The development also reflected cooperation between public research programs and a diagnostic manufacturer. The National Institutes of Health's RADx Tech Independent Test Assessment Program helped accelerate the evidence needed for FDA review, extending a testing-development approach used during the COVID-19 pandemic to another infectious disease. The broader goal was a more accessible connection between diagnosis and medicines already capable of curing many infections. Whether that promise became reality depended on staffing, treatment availability, payment, and the ability to reach people who needed care. June 27 marked a significant change in what a testing visit could accomplish, while leaving the larger work of connecting patients to treatment in the hands of health systems.
An antibody result and an RNA result answer different questions. Antibodies indicate exposure, while viral RNA can identify a current infection that needs clinical attention.
The significance of point-of-care testing was its location and speed. A useful diagnosis could be available before a person left the service where the sample was collected.
CLIA-waived use still required an appropriately certified setting and adherence to instructions. The decision did not make the test a consumer home-testing product.
A result could shorten the route to treatment, but could not guarantee medication access. The benefits depended on a working connection between testing and clinical care.
The NIH collaboration showed how diagnostic research infrastructure could support work beyond the pandemic. Validation and clinical evidence remained necessary for the new use.
The event belongs to the history of healthcare delivery as well as laboratory technology. It targeted the gap between a promising treatment and the people who could benefit from it.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.